SNSE Sensei Biotherapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
00:31
Jan 23
Jan 23
SNSE solnerstotug data drives upside
The author argues Sensei Biotherapeutics is a buy because its lead candidate solnerstotug showed meaningful responses and durable tumor shrinkage in hard-to-treat PD-(L)1 resistant tumors, a population with traditionally low response rates. The positive preliminary Phase 1/2 data and maintained enrollment momentum suggest potential therapeutic value in a high-unmet-need area. Heightened trading on strategic review optimism provides an additional sentiment-based catalyst, with no specific risk stated.
HIGH
About SNSE Investor Commentary
Across the available history and selected sources, Buzzberg tracks SNSE (Sensei Biotherapeutics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Careful_Economist352.